Boston Scientific BSX

NYSE · Surgical & Medical Instruments & Apparatus · $63.2B
$42.99−1.49%Nov 19 close · Databento
Every report since 2023 →

Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.

After a story on BSX, the first close moved a median −3.11%. Up 1 of 3; over the next three trading days, a median −3.33%.

The numbers

fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via Databento
Market cap$63.2B
EV / True FCF19.7x
Revenue$20.1B +19.9%
True FCF (ex-SBC)$3.4B +38.3%
Rule of 4038.1%
ROIC11.2%
True FCF Yield5.3%
EPS, diluted$1.94 +55.2%
Modern Valuation (EOD)
Market Cap$63.2B
Enterprise Value$66.2B
EV / True FCF19.71
EV / FCF18.10
EV / Gross Profit4.78
EV / EBIT18.32
EV / Sales3.30
P / E (GAAP)21.87
P / FCF17.29
P / Oper. CF13.95
P / Book2.58
Owner & Cash Yields
True FCF Yield5.3%
FCF Yield5.8%
Owner Earn. Yield4.9%
Earnings Yield4.6%
Shareholder Yield−0.5%
Buyback Yield0.0%
Dividend Yield—
Dividend / sh—
Payout Ratio0%
FCF / sh$2.52
EPS (diluted)$1.94
Compounder & Returns
Rule of 4038.1%
ROIC11.2%
Cash ROIC (CROIC)13.3%
GP / Assets31.7%
ROE11.8%
ROA6.6%
Gross Margin69.0%
Oper. Margin18.0%
Net Margin14.4%
FCF Margin18.2%
True FCF Margin16.7%
Quality & Dilution
Cash Conversion127%
Accrual Ratio−3.8%
SBC % of FCF8.2%
SBC % of Rev1.5%
Reinvest. Rate19%
Sales Growth Y/Y+19.9%
Sales 3Y CAGR+16.5%
EPS Growth Y/Y+55.2%
FCF Growth Y/Y+38.3%
FCF 3Y CAGR+57.4%
Share Change Y/Y+0.6%
Balance Sheet & Scale
Revenue (FY)$20.1B
Gross Profit (FY)$13.9B
Oper. Income (FY)$3.6B
GAAP Net Income$2.9B
True FCF (ex-SBC)$3.4B
Cash & Equiv$2.1B
Total Debt$5.1B
Net Cash (Debt)$-3.0B
Net Cash % MCap−4.7%
Debt / FCF (yrs)1.4y
Current Ratio1.621.45B sh
Price & Technicals (EOD)
Perf Week−2.74%
Perf Month−3.41%
Perf Quarter−14.65%
Perf Half Y−24.78%
Perf YTD−24.38%
SMA 20 Dist−2.32%$44.01
SMA 50 Dist−1.98%$43.86
SMA 100 Dist−5.31%$45.40
Window High−25.60%$57.78
Window Low+3.39%$41.58
RSI (14) · Vol45.445%v
Income Distribution & Cash Flow ConversionHow every dollar of BSX revenue flows through cost of goods, operating expenses, taxes, GAAP net income, and dilution-adjusted free cash flow
REVENUE · 100%$20.1BGROSS PROFIT · 69.0%$13.9BCOST OF REV · 31.0%$6.2BOPER. INCOME · 18.0%$3.6BOPEX · 51.0%$10.2B · SG&A $6.9BNET INCOME · 14.4%$2.9BTAX & OTHER · 3.6%$721.0M
Where Every $100 of Revenue Goes (FY2025)
Cost of Revenue (COGS)$6.2B ($31.0 / $100)
SG&A & Other OpEx$10.2B ($51.0 / $100)
Tax & Non-Operating$721.0M ($3.6 / $100)
Net Profit Kept$2.9B ($14.4 / $100)
Earnings Quality: GAAP Profit → True Owner Cash (FY2025)
GAAP Net Income$2.9B (14.4% margin)
Operating Cash Flow (OCF)$4.5B(22.6% of rev)
Less: Capital Expenditures−$876.0M(4.4% of rev)
Standard Free Cash Flow (FCF)$3.7B(18.2% margin)
Less: Stock-Based Comp (SBC)−$299.0M(8.2% of FCF)
True FCF (Owner Cash ex-SBC)$3.4B(16.7% of rev)

Operating leverage — margins

GrossOperatingNet
0%40%80%69%18%14%FY21FY22FY23FY24FY25
Unlocked SEC EDGAR Accounting Statements (USD)All 3 statements · Common-size (% of Revenue / Assets) · YoY growth · Tap any core row to explain
Line Item (USD)FY2021FY2022FY2023FY2024FY2025YoY Δ4Y CAGRTrend
Income Statement
Cost of Revenue (COGS)$3.7B$4.0B$4.3B$5.3B$6.2B+18.3%+13.8%
Selling, General & Admin (SG&A)$4.4B$4.5B$5.2B$6.0B$6.9B+15.1%+12.1%
Total Operating Expenses$7.0B$7.1B$7.6B$8.9B$10.2B+15.2%+10.1%
Interest Expense$341.0M$470.0M$265.0M$305.0M$349.0M+14.4%+0.6%
Income Tax Expense$36.0M$443.0M$393.0M$436.0M$493.0M+13.1%+92.4%
Diluted Shares1.43B1.44B1.46B1.49B1.49B+0.6%+1.0%
Balance Sheet
Cash & Equivalents$2.2B$1.1B$1.1B$606.0M$2.1B+254.3%−0.2%
Inventory$1.6B$1.9B$2.5B$2.8B$2.9B+4.7%+16.3%
Total Current Assets$6.3B$5.8B$6.5B$6.9B$8.8B+27.1%+8.6%
Total Assets$32.2B$32.5B$35.1B$39.4B$43.7B+10.9%+7.9%
Total Current Liabilities$4.3B$3.8B$4.9B$6.4B$5.4B−15.0%+6.2%
Total Debt (Short + Long Term)$5.1B$4.8B$5.3B$6.6B$5.1B−22.5%+0.2%
Stockholders' Equity$16.6B$17.6B$19.5B$22.0B$24.5B+11.2%+10.2%
Net Cash / (Net Debt)$-2.9B$-3.7B$-4.3B$-6.0B$-3.0B+50.5%—
Invested Capital$19.5B$21.3B$23.8B$28.0B$27.4B−2.0%+8.9%
Cash Flow & Capital Allocation
Depreciation & Amortization (D&A)$1.1B$1.1B$1.2B$1.3B$1.4B+7.8%+5.8%
Stock-Based Compensation (SBC)$194.0M$220.0M$233.0M$266.0M$299.0M+12.4%+11.4%
Capital Expenditures (CapEx)$554.0M$588.0M$711.0M$790.0M$876.0M+10.9%+12.1%
True FCF (ex-SBC Owner Cash)$1.1B$718.0M$1.6B$2.4B$3.4B+41.2%+31.5%
Share Repurchases (Buybacks)$0$0——$0——
Dividends Paid$55.0M$55.0M$28.0M$0$0——

Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.

On the Wire

what BSX did at the next close after each story

The record, by topic

last 90 days · stories · median first close
consumer1+4.82%
earnings1−5.90%
regulation1−3.11%
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.